Business updates for various pharma and life science companies around the globe.
What if you could detect cancer just as it is getting started? New research published in the journal Nature just might give medicine the tools to do just that.
CymaBay Therapeutics Inc. is scrapping two mid-stage trials of the liver disease drug seladelpar after biopsies found a type of liver damage in some patients, sending the company’s shares down more than 75 percent.
Researchers at the University of Strathclyde in Glasgow, Scotland, potentially developed a blood test for brain cancer using high-throughput attenuated total reflection (ATR)-Fourier transform infrared (FTIR) spectroscopy with machine learning.
Thrive Earlier Detection Corp., a liquid biopsy company, raised $110 million in Series A funding.
Researchers at Indiana University developed a blood test that could help more accurately diagnose post-traumatic stress disorder.
Personal Genome Diagnostics Inc. reported that the cancer genomics company’s 500+ gene pan-cancer tumor profiling tissue assay is being used in Merck’s Phase 2 precision oncology KeyImPaCT study of biomarker-directed, pembrolizumab-based combination therapy for advanced non-small-cell lung cancer (KEYNOTE-495).
The Nasdaq indicated that there was a record amount of biotech initial public offerings (IPOs) in 2018, totaling around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
Barring a last-minute reversal, 2018 will likely end as a down year for the biotech industry, at least in terms of stock performance.
Researchers from the University of Queensland’s Australian Institute for Bioengineering and Nanotechnology identified a nano-scaled DNA signature that seems to be common to all cancers.